Judge rules in favor of Illumina, countering FTC concerns over Grail merger

The ruling makes it more likely Illumina can retain its former subsidiary, which makes cancer diagnostics. The dispute is an important test case for the agency’s plans to more closely scrutinize life sciences mergers. 

Click here to view original post